Ilyang Pharmaceutical said on the 28th that its quadrivalent influenza vaccine "Teratect" has been approved by the Ministery of Food and Drug Safety for administration to infants and toddlers from 6 months old to under 3 years old.
Korea's National Immunization Program (NIP) for influenza vaccines covers children and adolescents from 6 months to 13 years old, pregnant women, and adults 65 and older. With this approval, the inoculation group, previously limited to those 3 and older, has been expanded to include infants and toddlers from 6 months old, which the company expects will have a positive impact on increasing orders for NIP supply volume.
An Ilyang Pharmaceutical official said, "We expanded our finished vaccine production line to improve profitability and expand sales," and added, "We will secure the recommended strains for circulation in the Southern Hemisphere and establish a production system that can operate year-round to expand our entry into the global market and participation in international bids."